SCHEMBL7149211

SCHEMBL7149211

COc1ccccc1NS(=O)(=O)CCCCSc1nc2ccccc2s1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
HSD17B10 Q99714 1/20 0.53
LMNA P02545 6/20 0.50
MAPT P10636 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 3/20 0.49
KMT2A Q03164 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
KDM4E B2RXH2 1/20 0.47
GFER P55789 1/20 0.47
NPC1 O15118 1/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 1/20 0.47
ALOX5 P09917 2/20 0.46
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148781 0.97 ALDH1A1 (0.54) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7149622 0.93 ALDH1A1 (0.59) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7146609 0.89 MAPT (0.42) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7149243 0.89 MAPT (0.51) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7148438 0.86 LMNA (0.64) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7153019 0.86 MAPT (0.43) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7151765 0.86 MAPT (0.52) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7154990 0.86 ALDH1A1 (0.49) ALDH1A1HSD17B10LMNAMAPTL3MBTL1
SCHEMBL7148433 0.84 KDM4E (0.46) ALDH1A1LMNAMAPTSMN1; SMN2HTT
SCHEMBL7149249 0.84 ALDH1A1 (0.53) ALDH1A1HSD17B10LMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885LMNA 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.